罗替戈汀山嵛酸酯对帕金森抑郁症大鼠的治疗作用OA

This experiment aims to explore the therapeutic effect of Rotigotine Behenate(ROTB)on depression in Parkinson's disease(DPD)rats.Rotigotine concentrations in rat plasma were determined by liquid chromatogra-phy-tandem mass spectrometry(LC-MS/MS).DPD rats were induced using 6-OHDA and CUMS and treated with ROTB at a doses of 5.6,11.2 and 22.4 mg/kg.The antidepressant effect of ROTB in DPD rats was assessed using forced swimming,open field,and sucrose preference tests.Expression levels of BDNF,TrkB,PI3K,Akt,p-Akt,GSK-3β and p-GSK-3β were measured by Western blot,while DA and 5-HT contents in the prefrontal cortex were analyzed by ELISA.Pathological changes in neurons in the prefrontal cortex were observed using HE staining.The results showed that a single intramuscular injection of ROTB enabled continuous and stable release of rotigotine for 28 days.ROTB alleviated depressive symptoms in DPD rats,potentially by up-regulating DA and 5-HT levels,enhancing the BDNF-TrkB and PI3K-Akt-GSK-3β signaling pathways,and reducing neuronal damage in the prefrontal cortex.These findings suggest that ROTB has therapeutic potential for treating depression in DPD rats.